Literature DB >> 18453594

Novel KIR3DL1 alleles and their expression levels on NK cells: convergent evolution of KIR3DL1 phenotype variation?

Rasmi Thomas1, Eriko Yamada, Galit Alter, Maureen P Martin, Arman A Bashirova, Paul J Norman, Marcus Altfeld, Peter Parham, Stephen K Anderson, Daniel W McVicar, Mary Carrington.   

Abstract

KIR3DL1 shows extensive polymorphism, and its variation has functional significance in terms of cell-surface expression levels and inhibitory capacity. We characterized nine KIR3DL1 alleles (*022, *028, *029, *033, *035, *051, *052, *053, and *054), four of which were identified for the first time in this study, and compared them to known alleles in phylogenetic analysis. Blood was available from eight individuals with these alleles, and cell-surface expression on NK cells could be determined for six of them using the KIR3DL1-specific Ab DX9. Four of the alleles were expressed at clearly detectable levels, and two others showed exceptionally low levels of expression. Site-directed mutagenesis demonstrated that single amino acid changes can result in either diminished or enhanced DX9 staining compared with the respective related KIR3DL1 allotypes. These results raise the possibility that KIR3DL1 evolution maintains variation in KIR3DL1 cell-surface expression levels, potentially due to the effect of such variation on functional capacity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18453594      PMCID: PMC2689389          DOI: 10.4049/jimmunol.180.10.6743

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  Involvement of inhibitory NKRs in the survival of a subset of memory-phenotype CD8+ T cells.

Authors:  S Ugolini; C Arpin; N Anfossi; T Walzer; A Cambiaggi; R Förster; M Lipp; R E Toes; C J Melief; J Marvel; E Vivier
Journal:  Nat Immunol       Date:  2001-05       Impact factor: 25.606

2.  Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism.

Authors:  C M Gardiner; L A Guethlein; H G Shilling; M Pando; W H Carr; R Rajalingam; C Vilches; P Parham
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

Review 3.  KIR: diverse, rapidly evolving receptors of innate and adaptive immunity.

Authors:  Carlos Vilches; Peter Parham
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

4.  Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS.

Authors:  Maureen P Martin; Xiaojiang Gao; Jeong-Hee Lee; George W Nelson; Roger Detels; James J Goedert; Susan Buchbinder; Keith Hoots; David Vlahov; John Trowsdale; Michael Wilson; Stephen J O'Brien; Mary Carrington
Journal:  Nat Genet       Date:  2002-07-22       Impact factor: 38.330

5.  Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002.

Authors:  Steven G E Marsh; Peter Parham; Bo Dupont; Daniel E Geraghty; John Trowsdale; Derek Middleton; Carlos Vilches; Mary Carrington; Campbell Witt; Lisbeth A Guethlein; Heather Shilling; Christian A Garcia; Katharine C Hsu; Hester Wain
Journal:  Hum Immunol       Date:  2003-06       Impact factor: 2.850

Review 6.  A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors.

Authors:  Jeffrey C Boyington; Peter D Sun
Journal:  Mol Immunol       Date:  2002-05       Impact factor: 4.407

7.  KIR locus polymorphisms: genotyping and disease association analysis.

Authors:  Maureen P Martin; Mary Carrington
Journal:  Methods Mol Biol       Date:  2008

8.  The D0 domain of KIR3D acts as a major histocompatibility complex class I binding enhancer.

Authors:  Salim I Khakoo; Ron Geller; Sunny Shin; Jomaquai A Jenkins; Peter Parham
Journal:  J Exp Med       Date:  2002-10-07       Impact factor: 14.307

9.  Plasticity in the organization and sequences of human KIR/ILT gene families.

Authors:  M J Wilson; M Torkar; A Haude; S Milne; T Jones; D Sheer; S Beck; J Trowsdale
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

10.  Different and divergent regulation of the KIR2DL4 and KIR3DL1 promoters.

Authors:  C Andrew Stewart; Jeroen Van Bergen; John Trowsdale
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422

View more
  34 in total

1.  Differential RNA expression of KIR alleles.

Authors:  Colum McErlean; Asensio A Gonzalez; Rodat Cunningham; Ashley Meenagh; Tanya Shovlin; Derek Middleton
Journal:  Immunogenetics       Date:  2010-05-08       Impact factor: 2.846

2.  KIR3DL1 genetic diversity and phenotypic variation in the Chinese Han population.

Authors:  S D Tao; Y M He; Y L Ying; J He; F M Zhu; H J Lv
Journal:  Genes Immun       Date:  2013-10-31       Impact factor: 2.676

3.  Impact of protective killer inhibitory receptor/human leukocyte antigen genotypes on natural killer cell and T-cell function in HIV-1-infected controllers.

Authors:  Costin Tomescu; Fuh-Mei Duh; Rebecca Hoh; Anne Viviani; Kara Harvill; Maureen P Martin; Mary Carrington; Steven G Deeks; Luis J Montaner
Journal:  AIDS       Date:  2012-09-24       Impact factor: 4.177

Review 4.  DCs and NK cells: critical effectors in the immune response to HIV-1.

Authors:  Marcus Altfeld; Lena Fadda; Davor Frleta; Nina Bhardwaj
Journal:  Nat Rev Immunol       Date:  2011-03       Impact factor: 53.106

5.  KIR3DL1/S1 Allotypes Contribute Differentially to the Development of Behçet Disease.

Authors:  Harry Petrushkin; Paul J Norman; Emma Lougee; Peter Parham; Graham R Wallace; Miles R Stanford; Farida Fortune
Journal:  J Immunol       Date:  2019-08-12       Impact factor: 5.422

6.  Killer Cell Immunoglobulin-like Receptor Variants Are Associated with Protection from Symptoms Associated with More Severe Course in Parkinson Disease.

Authors:  Kirsten M Anderson; Danillo G Augusto; Ravi Dandekar; Hengameh Shams; Chao Zhao; Tasneem Yusufali; Gonzalo Montero-Martín; Wesley M Marin; Neda Nemat-Gorgani; Lisa E Creary; Stacy Caillier; Mohammad R K Mofrad; Peter Parham; Marcelo Fernández-Viña; Jorge R Oksenberg; Paul J Norman; Jill A Hollenbach
Journal:  J Immunol       Date:  2020-07-24       Impact factor: 5.422

7.  Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1.

Authors:  Maureen P Martin; Vivek Naranbhai; Patrick R Shea; Ying Qi; Veron Ramsuran; Nicolas Vince; Xiaojiang Gao; Rasmi Thomas; Zabrina L Brumme; Jonathan M Carlson; Steven M Wolinsky; James J Goedert; Bruce D Walker; Florencia P Segal; Steven G Deeks; David W Haas; Stephen A Migueles; Mark Connors; Nelson Michael; Jacques Fellay; Emma Gostick; Sian Llewellyn-Lacey; David A Price; Bernard A Lafont; Phillip Pymm; Philippa M Saunders; Jacqueline Widjaja; Shu Cheng Wong; Julian P Vivian; Jamie Rossjohn; Andrew G Brooks; Mary Carrington
Journal:  J Clin Invest       Date:  2018-04-03       Impact factor: 14.808

8.  Analysis of binding of KIR3DS1*014 to HLA suggests distinct evolutionary history of KIR3DS1.

Authors:  Geraldine M O'Connor; Eriko Yamada; Andy Rampersaud; Rasmi Thomas; Mary Carrington; Daniel W McVicar
Journal:  J Immunol       Date:  2011-07-29       Impact factor: 5.422

9.  KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma.

Authors:  Christopher J Forlenza; Jeanette E Boudreau; Junting Zheng; Jean-Benoît Le Luduec; Elizabeth Chamberlain; Glenn Heller; Nai-Kong V Cheung; Katharine C Hsu
Journal:  J Clin Oncol       Date:  2016-04-11       Impact factor: 44.544

10.  Dimorphic motifs in D0 and D1+D2 domains of killer cell Ig-like receptor 3DL1 combine to form receptors with high, moderate, and no avidity for the complex of a peptide derived from HIV and HLA-A*2402.

Authors:  Deepti Sharma; Karine Bastard; Lisbeth A Guethlein; Paul J Norman; Nobuyo Yawata; Makoto Yawata; Marcelo Pando; Hathairat Thananchai; Tao Dong; Sarah Rowland-Jones; Frances M Brodsky; Peter Parham
Journal:  J Immunol       Date:  2009-09-14       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.